6 results
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
, 2023 and 2022 and 2021, respectively, primarily due to changes in capitalized R&D expenditures, net operating loss carry forwards, research
8-K
EX-99.1
SLRN
Acelyrin Inc
28 Mar 24
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
4:08pm
for late stage registrational studies and Biologic License Application-submission-enabling manufacturing activities.
R&D Expenses: Research
8-K
EX-99.3
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
Dis 2023;82:1404–1414 BE OPTIMAL; Merola et al Lancet 2023 401: 38–48 BE COMPLETE. Moonlake R&D day November 6, 2023 ARGO Part A week 12. (3 … . Ann Rheum Dis 2023;82:1404–1414 BE OPTIMAL; Merola et al Lancet 2023 401: 38–48 BE COMPLETE. Moonlake R&D day November 6, 2023 ARGO Part A week 12.
0
8-K
EX-99
SLRN
Acelyrin Inc
7 Nov 23
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
4:23pm
through key value-driving milestones across all three clinical programs.
R&D Expenses: Research and development expenses were $74.6 million
8-K
EX-99.1
SLRN
Acelyrin Inc
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm
30, 2023. The Company expects these to fund operations through key value-driving milestones across all three clinical programs.
R&D Expenses
8-K
EX-99.1
fxe2ci1n8ui7u
15 Jun 23
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
4:22pm
- Prev
- 1
- Next